Navafenterol - AstraZeneca
Alternative Names: AZD-8871; LAS-191351 - AstraZeneca; Navafenterol saccharinateLatest Information Update: 05 Nov 2023
At a glance
- Originator Almirall S.A.
- Developer Almirall S.A.; AstraZeneca
- Class Acetic acids; Antiasthmatics; Antibronchitics; Esters; Quinolines; Small molecules; Thiazoles; Triazoles
- Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Mar 2023 Discontinued - Phase-II for Chronic obstructive pulmonary disease in Germany, United Kingdom (Inhalation) due to strategic reasons(AstraZeneca pipeline, February 2023)
- 17 Sep 2019 Discontinued - Phase-I for Asthma in United Kingdom (Inhalation)
- 17 Sep 2019 AstraZeneca announces intention to submit regulatory applications for Chronic obstructive pulmonary disease in USA, European Union, Japan and China